Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in active idiopathic inflammatory myopathies
ISRCTN98762360Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Clinical improvement with glucocorticoid reduction at Week 52. Started May 2023; status: active, not recruiting.
02
Drugs
nipocalimab
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on ISRCTN98762360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98762360.